See more : Neueon Towers Limited (NTL.NS) Income Statement Analysis – Financial Results
Complete financial analysis of Panbela Therapeutics, Inc. (PBLA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Panbela Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- New Focus Auto Tech Holdings Limited (0360.HK) Income Statement Analysis – Financial Results
- Nickel Rock Resources Inc. (NICL.V) Income Statement Analysis – Financial Results
- Staidson (Beijing) BioPharmaceuticals Co., Ltd. (300204.SZ) Income Statement Analysis – Financial Results
- OJsys, Inc. (OJSY) Income Statement Analysis – Financial Results
- Sungshin Cement Co., Ltd (004985.KS) Income Statement Analysis – Financial Results
Panbela Therapeutics, Inc. (PBLA)
About Panbela Therapeutics, Inc.
Panbela Therapeutics, Inc., a clinical-stage biopharmaceutical company, together with its subsidiaries, focuses on developing disruptive therapeutics for the treatment of patients with cancer. The company focuses on diseases of the pancreas, including pancreatitis and pancreatic cancer, as well as neoadjuvant pancreatic cancer, colorectal cancer, ovarian cancer, and other agents in other cancer indications. Its lead product candidate is SBP-101, which is in Phase Ia/Ib clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma. The company was formerly known as Sun BioPharma, Inc. and changed its name to Panbela Therapeutics, Inc. in December 2020. Panbela Therapeutics, Inc. was incorporated in 2011 and is based in Waconia, Minnesota.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.36M | 973.81K | 1.23M | 699.76K |
| Cost of Revenue | 25.65M | 35.73M | 10.01M | 5.75M | 4.32M | 3.89M | 6.02M | 5.17M | 5.44M | 595.15K | 558.47K | 691.80K | 550.54K |
| Gross Profit | -25.65M | -35.73M | -10.01M | -5.75M | -4.32M | -3.89M | -6.02M | -5.17M | -5.44M | 761.84K | 415.35K | 540.90K | 149.21K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 56.14% | 42.65% | 43.88% | 21.32% |
| Research & Development | 20.61M | 28.05M | 5.42M | 2.51M | 2.35M | 1.78M | 2.59M | 2.50M | 2.85M | 2.37K | 279.79K | 0.00 | 0.00 |
| General & Administrative | 5.03M | 6.04M | 4.59M | 3.25M | 1.97M | 2.11M | 3.42M | 2.66M | 2.81M | 837.24K | 329.88K | 258.10K | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -217.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 5.03M | 6.04M | 4.59M | 3.25M | 1.97M | 2.11M | 3.42M | 2.66M | 2.59M | 837.24K | 329.88K | 258.10K | 253.72K |
| Other Expenses | 0.00 | -682.00K | -602.00K | 605.00K | -99.00K | -508.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 253.72K |
| Operating Expenses | 25.65M | 34.09M | 10.01M | 5.75M | 4.32M | 3.84M | 6.02M | 5.17M | 5.44M | 837.24K | 609.67K | 258.10K | 253.72K |
| Cost & Expenses | 51.29M | 34.09M | 10.01M | 5.75M | 4.32M | 3.84M | 6.02M | 5.17M | 5.44M | 1.43M | 1.17M | 949.90K | 804.26K |
| Interest Income | 123.00K | 14.00K | 1.00K | 17.00 | 2.19K | 0.00 | 1.00K | 2.00K | 8.00K | 4.00K | 18.41K | 0.00 | 0.00 |
| Interest Expense | -317.00K | 288.00K | 11.00K | 17.00K | 2.19M | 1.81M | 1.62M | 180.00K | 183.00K | 35.53K | 35.89K | 36.14K | 34.27K |
| Depreciation & Amortization | 0.00 | 16.36K | 10.01K | 5.75K | 4.32K | 3.89K | 6.02K | 5.17K | 8.00K | 9.58K | 8.79K | 5.64K | 3.10K |
| EBITDA | -51.29M | -34.76M | -10.61M | -5.15M | -4.42M | -1.76M | -6.02M | -5.17M | -5.12M | -75.40K | -194.32K | 289.44K | -101.40K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -4.56% | -17.16% | 23.40% | -14.49% |
| Operating Income | -51.29M | -34.09M | -10.01M | -5.75M | -4.32M | -3.89M | -6.02M | -5.17M | -5.44M | -75.40K | -194.32K | 282.80K | -104.50K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -5.56% | -19.95% | 22.94% | -14.93% |
| Total Other Income/Expenses | 25.85M | -956.00K | -613.00K | 691.00K | -2.29M | -2.27M | -4.89M | -285.00K | -564.00K | -31.53K | -17.48K | -35.14K | -33.69K |
| Income Before Tax | -25.45M | -35.05M | -10.62M | -5.06M | -6.62M | -6.16M | -10.91M | -5.45M | -5.68M | -106.92K | -211.80K | 247.66K | -138.20K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -7.88% | -21.75% | 20.09% | -19.75% |
| Income Tax Expense | -186.00K | -116.00K | -488.00K | -295.00K | -415.00K | -254.00K | -536.00K | -341.00K | -756.00K | 121.00 | 220.00 | 284.00 | 115.00 |
| Net Income | -25.26M | -34.93M | -10.14M | -4.77M | -6.20M | -5.91M | -10.37M | -5.11M | -4.93M | -107.04K | -212.02K | 247.38K | -138.31K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -7.89% | -21.77% | 20.07% | -19.77% |
| EPS | -232.43K | -40.75K | -20.77K | -14.80K | -26.10K | -1.52K | -3.49K | -1.97K | -4.20K | -892.03 | -1.77K | 2.06K | -1.15K |
| EPS Diluted | -232.43K | -40.75K | -20.77K | -14.80K | -26.10K | -1.52K | -3.49K | -1.97K | -4.20K | -892.03 | -1.77K | 2.06K | -1.15K |
| Weighted Avg Shares Out | 108.69 | 857.28 | 487.88 | 322.20 | 237.51 | 3.89K | 2.97K | 2.59K | 1.17K | 120.00 | 120.00 | 120.00 | 120.00 |
| Weighted Avg Shares Out (Dil) | 108.69 | 857.28 | 487.88 | 322.20 | 237.51 | 3.89K | 2.97K | 2.59K | 1.17K | 120.00 | 120.00 | 120.00 | 120.00 |
Panbela to Host First Quarter 2024 Earnings Conference Call on May 15, 2024
MINNEAPOLIS, May 01, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB: PBLA), (“Panbela”), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced that it will host a conference call on May...
Acceptance of Eflornithine (DFMO) Abstract for Oral Presentation at Digestive Disease Week
MINNEAPOLIS, April 30, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer today announced that an abstract for eflornithine, an inhibitor of polyamine synthesis, has...
Panbela Therapeutics Announces Interim Data Analysis for ASPIRE Trial Pushed to Q1 2025
Trial's lower-than-expected event rate suggests improved survival outcomes Trial's lower-than-expected event rate suggests improved survival outcomes
Panbela Announces Poster Presentation at American Association for Cancer Research:
Ivospemin/doxorubicin combination modulates polyamine metabolism to improve survival in murine ovarian cancer models Ivospemin/doxorubicin combination modulates polyamine metabolism to improve survival in murine ovarian cancer models
Panbela Announces Transfer to OTCQB Market
MINNEAPOLIS, April 16, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB: PBLA), (“Panbela”), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced that its common stock has been approved for quotation...
Panbela Therapeutics, Inc. (PBLA) Q4 2023 Earnings Call Transcript
Panbela Therapeutics, Inc. (PBLA) Q4 2023 Earnings Call Transcript
Panbela Provides Business Update and Reports Q4 and FY 2024 Financial Results
MINNEAPOLIS, March 26, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (NASDAQ:PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today provides a business update and reports financial results for the quarter and full year...
Panbela to Host Fourth Quarter and Year End 2023 Earnings Conference Call on March 26, 2024
MINNEAPOLIS, March 12, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), (“Panbela”), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced that it will host a conference call on March...
Top 4 Health Care Stocks That Are Preparing To Pump This Month - ProSomnus (NASDAQ:OSA), GRI Bio (NASDAQ:GRI)
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
Panbela Regains Compliance with Nasdaq Listing Standards for Bid Price and Publicly Held Shares Requirements
MINNEAPOLIS, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), (“Panbela”), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced that, has regained compliance with applicable listing standards...
Source: https://incomestatements.info
Category: Stock Reports